Due to the COVID-19 pandemic and postponement of ESPID 2020 to 26-29 October,

Late-Breaking Abstract Submission has been extended to 15 July.

There will also be several new sessions dedicated to pertinent topics, such as COVID-19 in paediatrics and more.

We are looking for (1) prospective studies for which results were not known at the time of the initial ESPID 2020 abstract deadline, but will be complete in time to present the results at ESPID 2020; as well as (2) important translational studies with emerging results.

Please explore the late-breaking abstract topics available below.

Late-Breaking General Topics

• Antimicrobials, diagnostics and infection control
  • Antimicrobials: resistance and pharmacology
  • Microbiological diagnostic tools
  • Healthcare-associated and surgical infections
• Public health and epidemiology
  • Population studies and surveillance
  • Modelling studies
• Vaccines
  • Vaccine development (phase 1-2) –  viral
  • Vaccine development (phase 1-2)  – bacterial and all non-viral
  • Vaccine efficacy (phase 3) and effectiveness – viral
  • Vaccine efficacy (phase 3) and effectiveness – bacterial and all non-viral
  • Vaccine safety (post licensure)
• Immunology & compromised host
  • Host-pathogen interaction
  • Host response diagnostics and imaging
  • Severe/systemic fungal infections
  • Infections in immunocompromised patients
• Global health
  • Zoonosis, vector-borne and emerging infections
  • Tropical/parasite infections & travel medicine
  • Refugees and migrants
• Infections in early life
  • Congenital and perinatal infections
• Respiratory infections
  • Upper respiratory infections and carriage studies
  • Lower respiratory infections and pneumonia
• Non-respiratory infections
  • Gastrointestinal infections
  • Urogenital infections
  • CNS infections
  • Systemic and multi-organ infections
• Mycobacteria and retroviruses
  •  Tuberculosis and other mycobacterial infections
  • HIV/AIDS
•  Others